A study for people looking to transition from Buprenorphine maintenance to VIVITROL
Brief description of study
Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Opioid Addiction, Opioid-Related Disorders
-
Age: Between 18 Years - 60 Years
-
Gender: All
Updated on
12 Jul 2022.
Study ID: 825716